tirzepatide 0.5 activates both GLP‑1 and GIP receptors, two hormone pathways that help regulate appetite, blood sugar, and how the body uses energy. This dual action is designed to promote fat loss while dependent insulinotropic polypeptide (GIP) and glucagon Zepbound 12.5 mg/0.5 mL injection

GLP-1 receptor agonists are transforming weight loss medicine, with semaglutide (Ozempic/Wegovy) delivering 12% weight loss and tirzepatide (Mounjaro/Zepbound) achieving 18% in clinical trials

The mechanism of action involves stimulating insulin secretion when blood glucose levels are elevated, whilst simultaneously suppressing glucagon release

In dermatology, it is highly prized for its ability to brighten skin from the inside out

Ozempic, , , FDA

Additionally, case 3 had evident ODD and multiple other risk factors

Key Takeaway: Fatigue is often a secondary effect of how the medication worksby reducing your appetite and changing how you process sugarrather than a direct toxin effect on your system